Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GTBP 
GT Biopharma Inc (GTBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: GTBP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.76% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.75M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta 1.33 | 52 Weeks Range 0.96 - 4.10 | Updated Date 08/15/2025 |
52 Weeks Range 0.96 - 4.10 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.63 |
Earnings Date
Report Date 2025-08-12 | When After Market | Estimate -0.68 | Actual -0.55 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -131.32% | Return on Equity (TTM) -538.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5030158 | Price to Sales(TTM) - |
Enterprise Value -5030158 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.09 | Shares Outstanding 3273000 | Shares Floating 1457849 |
Shares Outstanding 3273000 | Shares Floating 1457849 | ||
Percent Insiders 22.28 | Percent Institutions 16.7 |
Upturn AI SWOT
GT Biopharma Inc
Company Overview
History and Background
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies based on its TriKEu00ae technology platform. Founded in 2011, it aims to leverage the power of the immune system to treat cancer.
Core Business Areas
- TriKEu00ae Technology Platform: The core of GT Biopharma's business is its TriKEu00ae (Tri-specific Killer Engager) platform. This technology creates molecules designed to link an immune cell (natural killer or T cell) to a cancer cell, stimulating the immune cell to kill the cancer cell.
- Drug Development: GT Biopharma focuses on developing novel cancer immunotherapies based on the TriKEu00ae technology. Its lead product candidate is GTB-3550 TriKEu00ae, which targets CD33+ cancers like acute myeloid leukemia (AML).
Leadership and Structure
The leadership team consists of individuals with experience in biopharmaceutical development and oncology. The company structure includes research and development, clinical operations, and corporate management functions.
Top Products and Market Share
Key Offerings
- GTB-3550 TriKEu00ae: GTB-3550 is GT Biopharma's lead drug candidate for treating CD33+ acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). While specific market share data is unavailable due to its clinical stage, the target market consists of patients with relapsed/refractory AML and MDS. Competitors developing AML therapies include AbbVie/Genentech (Venclexta), Pfizer (Besponsa), and Novartis (Rydapt). It is too early to provide any meaningful revenue number.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high risk, high reward, and significant regulatory oversight. The market for cancer immunotherapies is rapidly expanding due to advancements in understanding the immune system and its interaction with cancer.
Positioning
GT Biopharma is positioned as a company specializing in targeted immunotherapies using its TriKEu00ae platform. Its competitive advantage lies in the potential to create novel immunotherapies with improved efficacy and safety profiles.
Total Addressable Market (TAM)
The total addressable market for AML therapies is estimated to be in the billions of dollars annually. GT Biopharma's success depends on the clinical success and commercialization of GTB-3550 TriKEu00ae and other TriKEu00ae-based therapies. With positive trials and subsequent regulatory approvals, it would be positioned to capture a meaningful share of this market.
Upturn SWOT Analysis
Strengths
- Novel TriKEu00ae technology platform
- Targeted immunotherapy approach
- Focus on unmet medical needs in oncology
- Potential for pipeline expansion
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of TriKEu00ae technology to other cancer types
- Positive clinical trial results for GTB-3550
- Accelerated regulatory pathways (e.g., breakthrough therapy designation)
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- ABBV
- PFE
- NVS
Competitive Landscape
GT Biopharma faces competition from established pharmaceutical companies with greater resources and approved therapies. Its advantage lies in the potential of its novel TriKEu00ae technology and targeted immunotherapy approach. ABBV, PFE, and NVS have significantly broader pipelines, greater capital, and established commercial infrastructure. GTBI is highly dependent on a few compounds.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by advancements in its TriKEu00ae technology and progress in clinical trials.
Future Projections: Future growth is dependent on the successful clinical development and commercialization of GTB-3550 and other TriKEu00ae-based therapies. Analyst estimates vary based on clinical trial outcomes and market potential.
Recent Initiatives: Recent initiatives include advancing GTB-3550 through clinical trials, exploring new TriKEu00ae applications, and securing partnerships.
Summary
GT Biopharma is a high-risk, high-reward clinical-stage biopharmaceutical company with a promising TriKEu00ae technology platform. Its success hinges on positive clinical trial outcomes, securing partnerships, and navigating the regulatory landscape. The company needs to mitigate its cash burn and competition, while focusing on executing successful trials. Therefore, it is considered a risky stock that is highly speculative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share percentages are rough estimates. Financial data might be lagging.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GT Biopharma Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2017-09-22 | CEO & Executive Chairman Mr. Michael Martin Breen L.L.B. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.gtbiopharma.com |
Full time employees 1 | Website https://www.gtbiopharma.com | ||
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.